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INTRODUCTION
Sudden sensorineural hearing loss (SSNHL) is defined as a 30 dB or greater sensorineural hearing loss over at least three consecutive 
frequencies occurring within 72 hours. The etiology is, in most cases, unknown and may include infections, vascular accidents, trau-
mas, tumors, endolymphatic hydrops, and autoimmune disorders [1]. Recovery depends on several factors, including age, associated 
symptoms such as tinnitus and vertigo, severity of hearing impairment, and the time lapse between the onset and treatment [1].
Concerning its recurrence, the literature is very heterogeneous: the incidence varies from 0.8% to 47% [2-6]. A higher recurrence rate 
was reported at low  frequencies SSNHL. Approximately 9% of cases with SSNHL develops Menière’s disease, but only some cases 
of SSNHL involving low frequencies develop this disease [6]. The evolution of hearing loss over time was studied in endolymphatic 
hydrops [7], but not in SSNHL.
When assessing the evolution of hearing loss over time, it is important to consider the effect of aging on the cochlear function. 
There is a lack of literature regarding the effect of aging on affected and unaffected ear of subjects with SSNHL. Moreover, no study 
analyzed the correlation between the hearing evolution over time and clinical features. Guidelines did not report any recommen-
dations about a long-term follow-up of patients with SSNHL [1].
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OBJECTIVES: The recurrence rate of sudden sensorineural hearing loss (SSNHL) varies from 0.8% to 40%. However, to the best of our knowledge, 
no data on long-term hearing variations are present in the literature. The aim of this observational study was to analyze long-term variations of 
the hearing threshold in unilateral SSNHL without recurrence.
MATERIALS and METHODS: A total of 50 patients affected by unilateral SSNHL were evaluated. Patients underwent a treatment consisting of 
intravenous corticosteroids. Clinical and audiometric features were recorded. Patients underwent pure tone audiometry at a mean follow-up of 
5.26±2.28 years. Differences between the affected and unaffected ear were analyzed.
RESULTS: Comparing the post-treatment and follow-up audiograms, there was a worsening of hearing in the unaffected ear. On the contrary, no 
significant difference over time was found for the affected ear. 54% of patients showed no changes over time, 26% showed worsening, and 20% 
showed an improvement in hearing. The variation correlated with alcohol consumption and the presence of vasculopathies. An average improve-
ment of hearing over time was observed at low frequencies.
CONCLUSION: The time evolution in SSNHL is not predictable on the basis of the clinical and audiometric data. The majority the patients shows no 
changes in hearing loss in the affected ear. Patients who consume alcohol or have vasculopathies also have a higher risk of worsening of hearing. 
Further prospective studies are mandatory to better assess variations over time and their relationship with the effect of aging on hearing.
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The aim of this observational study was to analyze long-term vari-
ations of the hearing threshold in unilateral SSNHL without recur-
rence. Correlations with clinical characteristics were assessed.
MATERIALS AND METHODS
A total of 50 patients observed for unilateral SSNHL between 2007 
and 2015 were included in this observational study. Exclusion criteria 
were as follows: vertigo at onset, Menière’s disease, trauma, ototox-
icity, vestibular schwannoma, Cogan syndrome, concomitant neuro-
logical symptoms, and recurrence of SSNHL. Clinical and audiomet-
ric data were recorded. All procedures were in accordance with the 
ethical standards of the institutional research committee and with 
the 1964 Helsinki Declaration and its later amendments or compa-
rable ethical standards. Approval by the Institutional Review Board 
was not needed because of the retrospective nature of the study. In-
formed consent was obtained from all participants included in the 
study.
After diagnosis, each patient was treated with intravenous cortico-
steroids (betamethasone 4 mg per day: Bentelan, Alfasigma, Milano, 
Italy) and mannitol (18% 250 mL per day: Mannitolo, Fresenius Kabi 
Italia, Verona, Italy) for 5 days. Eighteen patients (36%) underwent a 
second cycle of intravenous therapy. Five patients (10%) underwent 
hyperbaric oxygen therapy in addition to medical treatment (three 
patients before and two after it). Intratympanic corticosteroids were 
administered to four patients after intravenous therapy (8%). Seven 
patients (14%) continued with oral corticosteroids for 8 days.
Pre-, post-treatment, and follow-up pure tone audiometry (PTA) was 
recorded analyzing the severity of hearing loss, audiogram curve 
morphology, and hearing recovery. Each patient underwent PTA at 
the end of treatment, 1 and 6 months after treatment, and then once 
a year. For this study we considered the first and the last audiogram 
after the treatment. Average PTA at 0.5, 1, 2, and 4 kHz (speech fre-
quencies) was calculated. The severity of hearing loss was based on 
the PTA threshold as follows: mild (25-40 dB HL), moderate (41-55 
dB HL), moderately severe (56-70 dB HL), severe (71-90 dB HL), and 
profound (>90 dB HL) [1]. Audiometric curve morphology was classi-
fied as upward-sloping curves, downward-sloping curves, flat loss, 
or trough shaped curves [1]. Guidelines criteria for hearing recovery 
were used [1]. Audiograms variation over time during the follow-up 
was classified as follows: improvement (improved hearing thresh-
olds ≥10 dB HL on all the frequencies, compared to post-treatment 
audiogram); worsening (worsened hearing thresholds ≥10 dB HL on 
all the frequencies, compared to post-treatment audiogram); and no 
change (improved or worsened hearing thresholds within 10 dB HL, 
compared to post-treatment audiogram).
The mean age of the study group was 53.02±13.84 years (range, 17-
88 years). Nine patients (18%) were older than 60 years. The mean 
age at the onset of SSNHL was 47.36±14.63 years (range, 11-82 
years). Table 1 reports patient characteristics. Alcohol consumption 
was defined as the consumption of more than one drink per day. 
Vasculopathies included diseases of the arteries of the heart, brain, 
neck, and lower limbs. The mean follow-up was 5.26±2.28 years 
(range, 1-9 years). Forty-three patients (86%) had at least a 2-year fol-
low-up, while 27 (54%) had a 5-year follow-up. Encephalic magnetic 
resonance imaging scans with contrast medium did not identify any 
vestibular schwannomas.
Statistical Analysis
All statistical analyses were carried out using the Statistical Package 
for Social Sciences, version 20.0 (IBM Corp., Armonk, NY, USA). A de-
scriptive analysis of all data was performed, and they were reported 
as means or percentages and standard deviations. The Kolmogorov–
Smirnov test demonstrated a non-Gaussian distribution of variables, 
so non-parametric tests were used. The Friedman test was used to as-
sess differences among more than two paired groups in the mean of 
continuous variables. Post-hoc testing involved the Wilcoxon signed-
rank test. The Bonferroni method was used to have a stricter crite-
rion on whether to accept an effect as significant. The Mann-Whit-
ney U test was used to assess differences between two independent 
groups in the mean of continuous variables. The chi-squared test was 
used for categorical variables. A p<0.05 was considered statistically 
significant.




Flat loss 16 (32%)
Trough shaped  0 (0%)
Hearing loss (based on average PTA)
Mild (25-40 dB HL) 28 (56%)
Moderate (41-55 dB HL)  6 (12%)
Moderate-severe (56-70 dB HL)  2 (4%)
Severe (71-90 dB HL)  9 (18%)
Profound (>90 dB HL)  5 (10%)
PTA: pure tone audiometry









Tinnitus on onset 30 (60%)
Tinnitus in the next years 25 (50%)
Systemic hypertension 11 (22%)
Diabetes mellitus 0 (0%)
Dyslipidemia 13 (26%)
Vasculopathies 11 (22%)
Previous chemotherapy 3 (6%)
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RESULTS
The distribution of audiogram patterns and degree of hearing loss 
in our sample are reported in Table 2. Most patients had a down-
ward-sloping or flat hearing loss at audiogram. Hearing loss was 
mainly mild (56% of cases), and 14 (28%) patients were affected by a 
severe/profound hearing loss.
The mean time between the onset and therapy was 11.52±14.58 
days (range, 0-60 days). The treatment was administered seven or 
more days after the appearance SSNHL in 17 patients (34%). Com-
plete recovery occurred in 13 patients (26%), partial recovery in 19 
(38%), and no recovery in 18 (36%).
Table 3. PTA values (dB HL), as mean±standard deviation, with p values 
between the post-treatment and follow-up evaluations
Affected ear
 Pre-treatment Post-treatment Follow-up p
250 Hz 45.90±28.73 34.40±25.77 30.70±24.91 0.092
500 Hz 46.90±29.74 35.30±28.04 31.40±24.83 0.051
1000 Hz 45.90±31.47 34.30±27.55 33.60±26.63 0.509
2000 Hz 44.20±29.28 34.80±27.29 35.50±27.47 0.778
3000 Hz 50.70±28.39 39.30±26.59 40.80±28.06 0.873
4000 Hz 53.70±29.10 43.90±27.50 46.80±28.24 0.329
6000 Hz 60.80±26.71 51.00±28.77 53.70±28.66 0.433
8000 Hz 62.30±28.98 53.10±30.07 54.59±31.17 0.438
Average PTAa 47.68±27.99 37.08±26.22 39.70±25.75 0.850
Unaffected ear
 Pre-treatment Post-treatment Follow-up p
250 Hz 18.40±9.66 18.10±9.58 20.70±11.16 <0.001
500 Hz 18.30±11.94 18.30±12.06 20.50±12.17 0.001
1000 Hz 18.80±12.10 18.60±11.78 20.70±13.05 0.001
2000 Hz 20.20±14.10 19.60±12.73 23.30±16.65 <0.001
3000 Hz 22.40±15.72 21.90±14.46 24.60±17.20 0.001
4000 Hz 24.10±17.13 23.60±16.41 27.30±19.36 0.001
6000 Hz 30.00±21.04 29.00±20.87 32.50±21.91 0.016
8000 Hz 32.40±23.95 32.00±23.58 36.60±25.80 0.006
Average PTAa 20.35±12.98 20.03±12.40 25.11±15.36 <0.001
Difference between the affected and unaffected ear
 Pre-treatment Post-treatment Follow-up
250 Hz 28.80±28.10 17.50±26.09 11.50±25.32
500 Hz 30.30±29.06 18.70±28.30 12.60±24.56
1000 Hz 28.80±30.45 17.30±27.32 14.70±25.98
2000 Hz 25.90±27.64 16.80±26.60 14.50±26.64
3000 Hz 29.90±26.41 18.80±26.10 18.20±26.65
4000 Hz 31.30±26.26 21.80±26.55 21.60±25.52
6000 Hz 32.80±24.44 24.00±28.05 23.10±26.51
8000 Hz 32.00±26.24 23.00±28.84 19.20±28.42
Average PTAa 29.16±26.39 18.73±25.78 15.93±24.19
PTA: pure tone audiometry; aAverage PTA on 0.5, 1, 2, and 4 kHz
Table 4. Correlation tests for audiogram variation over time
 p
Sex 0.573







Tinnitus on onset 0.710
Time before treatment >7 days 0.886
Audiogram morphology 0.412
Hearing loss >70 dB 0.086
Difference between the affected and unaffected ear >30 dB 0.125
Recovery 0.222
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Figure 1. Average PTA on 0.5, 1, 2, and 4 kHz (unaffected and affected ear) at 






















Unaffected ear Affected ear
Average PTAs at 0.5, 1, 2, and 4 kHz at diagnosis, after treatment, 
and at follow-up are reported in Table 3. Differences between the 
first post-treatment control and follow-up evaluation were sig-
nificant at the Wilcoxon signed-rank test only for the unaffected 
ear (p<0.05). After the follow-up, the mean data showed a slight 
non-significant improvement of the PTA threshold of the affected 
ear and a significant worsening of the hearing threshold of the un-
affected ear (Table 3). This pattern is better evidenced in Figures 1 
and 2. Figure 1 compares the mean PTA values before treatment, 
immediately after treatment, and at the last follow-up, while in Fig-
ure 2 the mean audiograms are reported, on the basis of the val-
ue at each frequency tested. Figure 2 and Table 3 show how the 
threshold difference between the affected and the unaffected ear 
decreased after a long follow-up.
An average PTA correlated with aging at the pre-treatment, 
post-treatment, and follow-up evaluation (p<0.05 at the Mann-Whit-
ney U test). Figure 1 highlights that the difference between patients 
Figure 3. Differences between the post-treatment and follow-up audiograms. 
Data on the entire sample and according to audiogram morphology are shown 
(10 cases with upward-sloping curves, 24 with downward-sloping curves, and 
16 with flat loss).
Figure 2. Average audiograms at the pre-treatment, post-treatment, and fol-
low-up evaluation.
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aged <60 and >60 years was more evident for the unaffected ear, 
compared to the affected one. In particular, older patients showed a 
higher PTA threshold of the unaffected ear, while the PTA threshold 
of the affected ear was similar to younger patients.
Comparing differences over time (post-treatment vs. follow-up) be-
tween the unaffected and affected ear at each frequency, they were 
significant only at 250 and 500 Hz (p<0.05 at the Wilcoxon signed-
rank test; Figure 3a). It was more evident in the cases of upward-slop-
ing curves and flat loss (Figures 3b, 3c, and 3d).
The analysis of the differences over time (post-treatment vs. fol-
low-up) for the unaffected and affected ear did not show any signifi-
cance comparing patients with and without 5-year follow-up (p>0.05 
at the Mann-Whitney U test). Therefore, the passage of time after the 
SSNHL seemed to not affect the difference in the PTA threshold in 
both ears. However, a great standard deviation (as noticeable in Fig-
ure 3) was present and could be the reason for the absence of signif-
icance. Moreover, there was no correlation between the degree of 
recovery and differences over time (p>0.05 at the Mann-Whitney U 
test), neither in the unaffected ear nor in the affected one.
For the affected ear, 27 patients (54%) showed no changes over time, 
13 cases (26%) showed worsening, and 10 cases (20%) showed an im-
provement in hearing, according to our classification of audiograms 
variation over time (Figure 4). The variation was correlated with al-
cohol consumption and the presence of vasculopathies (p<0.05 at 
the chi-squared test) (Table 4). Patients who consume alcohol or have 
vasculopathies have a higher risk of worsening of hearing. On the 
contrary, there was no correlation between the audiograms variation 
over time and the degree of recovery after treatment (p<0.05 at the 
chi-squared test).
DISCUSSION
SSNHL has controversial etiologies, treatments, and prognosis. The 
cause can be identified only in a small percentage of cases (approxi-
mately 10%) [1]. The literature indicates several risk factors for SSNHL, 
in particular cardiovascular factors [8-10]. The treatment is generally 
based on corticosteroids, and prognosis varies from absent to com-
plete recovery [1].
Previous studies focused on post-treatment auditory recovery and 
recurrences [2-6, 11, 12]. Approximately 25%-33% of cases had complete 
recovery of the auditory function 2 weeks after the event, a similar 
percentage had no recovery, while a partial recovery could affect up 
to 50% of patients [1, 11]. Subjective feelings for residual tinnitus are 
almost the same at 6 and 24 months after the SSNHL treatment [12]. 
However, no study analyzed long-term audiometric outcomes in 
SSNHL. Not even the clinical practice guidelines report recommen-
dations about a long-term follow-up [1].
Many factors can affect the post-treatment auditory recovery. Age, 
downward-sloping curves, the severity of hearing loss, and the time 
lapse between the onset and treatment seems to be a negative fac-
tor on recovery [11, 14-15]. Concerning the relapse, the literature is very 
heterogeneous: the incidence varies from 0.8% to 47% [2-6]. A higher 
recurrence rate was reported for low frequencies SSNHL [6]. Approxi-
mately 9% of cases with SSNHL develops Menière’s disease, but not 
all SSNHLs involving low frequencies develop to this disease (ap-
proximately 23%) [16-18]. Contrary to the literature, in our study, no 
patient with the SSNHL involving low tones developed Menière’s 
disease.
The effect of aging on the cochlear function in subjects without ear 
disease and without occupational exposure to noise is well known 
[19]. A mathematical model based on a population without the occu-
pational exposure to noise allows for the prediction of a PTA thresh-
old at different frequencies in relation to age (ISO 7029-2000) [20]. In 
particular, it is known that aging mainly affects high frequencies. 
Our study analyzed the audiometric evolution over time in patients 
with previous SSNHL, comparing the affected and unaffected ear. 
Basing on our criteria, 54% of subjects showed no changes over 
time, 26% showed worsening, and 20% an improvement of hearing 
over time, after a mean follow-up of 5.26±2.28 years. Interestingly, 
aging seemed to effect on average the unaffected ear but not the 
ears with SSNHL. We can speculate that aging begins to influence 
the ear with previous SSNHL only when the other ear reaches the 
audiometric threshold of the affected ear [19]. Thus, the effects of 
presbycusis and SSNHL seems to be non-additive. The reason could 
be the possible common damage on inner hairy cells and/or audi-
tory nerve fibers. Generally, we can say that, after SSNHL, the affect-
ed ear shows a stability in the hearing loss over time, compared to 
the unaffected one.
Our analysis of the hearing variation during the follow-up showed 
that its evolution over time was not influenced by the degree of 
post-treatment recovery. However, patients who recovered com-
pletely after the initial treatment did not improve further, and few 
got worse.
The difference between the threshold values of the affected and 
unaffected ear at the follow-up audiogram could be considered the 
effect of SSNHL on the cochlear function over time. An average im-
provement of hearing over time was observed at low frequencies. 
It was more evident in cases of upward-sloping curves and flat loss. 
However, a great standard deviation was present. Therefore, further 
studies with larger samples are needed to correctly evaluate this time 
trend. Moreover, a specific focus on low-frequency SSNHL should be 
set to better assess the possibility of an endolymphatic hydrops in 
Figure 4. Audiograms variation over time.
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such cases. Because of the fluctuating nature of hearing loss in the 
initial phase of endolymphatic hydrops, prospective studies are re-
quired to analyze when the improvement of hearing at low frequen-
cies occurs in patients with SSNHL.
The presence of vasculopathy and alcohol consumption was associ-
ated with a worse long-term prognosis. This is in compliance with the 
studies that identified vascular risk factors, like smoking, that affect 
hearing [21].
The limits of our study include the presence of heterogeneous treat-
ments and a small number of patients. Therefore, this retrospective 
study may be considered a pilot study, with the need of further pro-
spective studies on larger samples.
CONCLUSION
The evolution over time of SSNHL is not predictable on the basis of 
the clinical and audiometric data. However, the majority of cases 
shows a stability of hearing in the affected ear, compared to the un-
affected one. Further prospective studies are mandatory to better as-
sess the variations over time, prognostic factors, and the relationship 
with the effect of aging on hearing.
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